STRATEGY
EXPORT TO 96 COUNTRIES
NCE – DPOCL
In 1978, Centaur Pharmaceuticals, commenced pharmaceutical manufacturing operations in Mumbai and has now evolved into a vertically integrated pharmaceutical company. Centaur House, our corporate headquarters, is located in Mumbai, the commercial capital of India. Centaur has a strong matrix of capabilities across the pharmaceutical value chain including API, formulations, Contract Research and Manufacturing Services, Clinical Research, R&D, regulatory and marketing.
Exports to 96 countries across five continents, is vindication of Centaur’s commitment to quality, and global acceptance by discerning doctors, patients and clients. Forty two percent of our sales accrue from international markets.
With a world-class infrastructure and key initiatives across people, processes and practices, Centaur is poised to leverage synergies across the pharmaceutical spectrum and provide end-to-end solutions to prestigious pharmaceutical partners.
Centaur has successfully co-developed a Globally Patented New Chemical Entity (NCE), DPOCL , for the treatment of Diabetic Foot Ulcer, an unmet medical need. Centaur’s clinical research division, Lifesan, collaborated with a German biotechnology company and successfully conducted Phase II and III studies in India. Centaur is awaiting marketing approval to introduce the NCE for the first time in the world, in India.
Our most precious assets are the 2776 Centaurians working diligently for the organisation across our facilities, head office and sales teams.
Centaur has set ambitious growth plans which it hopes to achieve by
- Leveraging integration synergies
- Sharpening international focus
- Entering into strategic alliances
- In-licensing molecules
We believe that a strategic global approach will widen our geographical spread, enhance business volumes, derisk our revenue streams and help us carve out a niche in the global pharmaceutical market.